268 related articles for article (PubMed ID: 17667522)
1. Exploiting regulatory T-cell populations for the immunotherapy of cancer.
van der Vliet HJ; Koon HB; Atkins MB; Balk SP; Exley MA
J Immunother; 2007 Sep; 30(6):591-5. PubMed ID: 17667522
[TBL] [Abstract][Full Text] [Related]
2. Multiple roles for CD4+ T cells in anti-tumor immune responses.
Kennedy R; Celis E
Immunol Rev; 2008 Apr; 222():129-44. PubMed ID: 18363998
[TBL] [Abstract][Full Text] [Related]
3. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms.
Lizée G; Radvanyi LG; Overwijk WW; Hwu P
Clin Cancer Res; 2006 Aug; 12(16):4794-803. PubMed ID: 16914564
[TBL] [Abstract][Full Text] [Related]
4. Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells.
Khan S; Burt DJ; Ralph C; Thistlethwaite FC; Hawkins RE; Elkord E
Clin Immunol; 2011 Jan; 138(1):85-96. PubMed ID: 21056008
[TBL] [Abstract][Full Text] [Related]
5. [Influence of regulatory T cells on the functioning of natural killer cells during cancer immunotherapy].
Chikileva IO; Shubina IZh; Kiselevskiĭ MV
Vestn Ross Akad Med Nauk; 2012; (4):60-4. PubMed ID: 22834330
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
Braza MS; Klein B
Br J Haematol; 2013 Jan; 160(2):123-32. PubMed ID: 23061882
[TBL] [Abstract][Full Text] [Related]
7. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer.
Wang RF
Hum Immunol; 2008 Nov; 69(11):811-4. PubMed ID: 18817828
[TBL] [Abstract][Full Text] [Related]
8. The path to reactivation of antitumor immunity and checkpoint immunotherapy.
Kim HJ; Cantor H
Cancer Immunol Res; 2014 Oct; 2(10):926-36. PubMed ID: 25281320
[TBL] [Abstract][Full Text] [Related]
9. Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?
Zhang L; Dermawan KT; Jin ML; Xiong SD; Chu YW
Med Hypotheses; 2008 Nov; 71(5):802-4. PubMed ID: 18691831
[TBL] [Abstract][Full Text] [Related]
10. NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis.
Terabe M; Berzofsky JA
Trends Immunol; 2007 Nov; 28(11):491-6. PubMed ID: 17964217
[TBL] [Abstract][Full Text] [Related]
11. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.
Fujii S
Trends Immunol; 2008 May; 29(5):242-9. PubMed ID: 18372215
[TBL] [Abstract][Full Text] [Related]
12. Control of immune responses by immunoregulatory T cells.
Rudge G; Gleeson PA; van Driel IR
Arch Immunol Ther Exp (Warsz); 2006; 54(6):381-91. PubMed ID: 17122882
[TBL] [Abstract][Full Text] [Related]
13. NKT cells and tumor immunity--a double-edged sword.
Smyth MJ; Godfrey DI
Nat Immunol; 2000 Dec; 1(6):459-60. PubMed ID: 11101862
[No Abstract] [Full Text] [Related]
14. Immune responses in hepatocellular carcinoma.
Korangy F; Höchst B; Manns MP; Greten TF
Dig Dis; 2010; 28(1):150-4. PubMed ID: 20460904
[TBL] [Abstract][Full Text] [Related]
15. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
Ghiringhelli F; Ménard C; Terme M; Flament C; Taieb J; Chaput N; Puig PE; Novault S; Escudier B; Vivier E; Lecesne A; Robert C; Blay JY; Bernard J; Caillat-Zucman S; Freitas A; Tursz T; Wagner-Ballon O; Capron C; Vainchencker W; Martin F; Zitvogel L
J Exp Med; 2005 Oct; 202(8):1075-85. PubMed ID: 16230475
[TBL] [Abstract][Full Text] [Related]
16. Regulatory T cells: potential target in anticancer immunotherapy.
Juang CM; Hung CF; Yeh JY; Horng HC; Twu NF; Cheng MH; Wen KC; Yuan CC; Chao KC; Wu TC; Yen MS
Taiwan J Obstet Gynecol; 2007 Sep; 46(3):215-21. PubMed ID: 17962099
[TBL] [Abstract][Full Text] [Related]
17. Foxp3(high) and Foxp3(low) Treg cells differentially correlate with T helper 1 and natural killer cells in peripheral blood.
Lee SK; Kim JY; Jang BW; Hur SE; Na BJ; Lee M; Fukui A; Gilman-Sachs A; Kwak-Kim J
Hum Immunol; 2011 Aug; 72(8):621-6. PubMed ID: 21600259
[TBL] [Abstract][Full Text] [Related]
18. [An efficient methods for the induction of human antitumor effector CD4+ and CD8+ T cells: their application to tumor immunotherapy].
Nishimura T; Kuge S; Watanabe K; Lee U; Yahata T; Habu S
Hum Cell; 1994 Sep; 7(3):131-7. PubMed ID: 7873496
[TBL] [Abstract][Full Text] [Related]
19. Interferon-α suppresses cAMP to disarm human regulatory T cells.
Bacher N; Raker V; Hofmann C; Graulich E; Schwenk M; Baumgrass R; Bopp T; Zechner U; Merten L; Becker C; Steinbrink K
Cancer Res; 2013 Sep; 73(18):5647-56. PubMed ID: 23878189
[TBL] [Abstract][Full Text] [Related]
20. "Up-dating the monograph." [corrected] Cytolytic immune lymphocytes in the armamentarium of the human host.
Sinkovics JG
Acta Microbiol Immunol Hung; 2008 Dec; 55(4):371-82. PubMed ID: 19130745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
